Furthermore, ATRA facilitated OTUD6B ptotein expression, and its combination enhanced the responsiveness of ESCC tumors to anti-PD-1 immunotherapies [8]. The gene discussed is OTUD6B; the disease is esophageal squamous cell carcinoma.